ESPE Abstracts (2019) 92 P2-158

GH and IGFs

Clinical and Genetic Characteristics of Eleven Korean Patients with Hypochondroplasia and Outcomes of Growth Hormone Therapy

Min-Sun Kim1, Minji Im1, Hyojung Park 1, Mi Jung Park2, Shin Hye Kim2, Sung Yoon Cho1, Dong-Kyu Jin1


1Department of Pediatrics, Samsung Medical Center, Seoul, Korea, Republic of. 2Department of Pediatrics; Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of

Hypochondroplasia (HCH) is an autosomal dominant inherited skeletal dysplasia with abnormal growth pattern and inadequate pubertal growth spurt. Achondroplasia and HCH have many similar phenotype, however, HCH show the mildest phenotype among FGFR3-associated skeletal dysplasia, and the radiologic findings are usually so subtle. We investigated to evaluate clue for the hypochondroplasia, and clinical and genetic characteristics of eleven Korean patients with HCH. We also demonstrate the growth promoting effect of a recombinant growth hormone (rGH) treatment in three patients with HCH.

Clinical data were obtained from the medical records of eleven patients with HCH from ten unrelated families. The data included height, brachydactyly, genu varum, lumbar lordosis, generalized laxity, limitation of elbow extension, macrocephaly, and mental retardation. Radiological evaluations were performed. The FGFR3 mutational status was studied by FGFR3 whole exome sequencing. Effectiveness of rGH therapy was analyzed in three patients.

All patients showed brachydactyly. Six patients showed definitely short stature (less than −2 SDS), but other five patients did not show significant short stature (mean Height SDS −2.54 vs −1.68 respectively). Genu varum was observed in six patients. Radiographic features revealed failure of widening of the inferior lumbar interpedicular distance, metaphyseal flaring, squared and short ilia, flattened acetabular roofs, and elongation of distal fibula with varied frequencies. The FGFR3 gene analysis revealed one novel mutation (p.Thr330Ile) in one patient and four known mutations were detected in nine patients (p.Lys650Asn, p.Lys650Thr and p.Ser84Leu were found in each 3 proband, and p.Asn540Lys in the other six probands). Three patients who received rGH, the mean height SDS increased by average 0.274 per year during the study period. The mean SDS of baseline IGF-1 value was −0.275 before rGH treatment and 0.630 ± 0.848 during the last year of observation.

Detailed investigations of radiologic features of HCH are important because of a mild or sometimes an absent phenotype. FGFR3 whole exon sequencing is a useful method because HCH has variable mutation positions. rGH treatment durably improves growth in children with of HCH. Improvement of body disproportion should be studied in the further study.

Keywords: hypochondroplasia, FGFR3 mutation, clinical characteristics and recombinant growth hormone therapy

Volume 92

58th Annual ESPE meeting

Vienna, Austria
19 Sep 2019 - 21 Sep 2019

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts

No recent abstracts.